3/26
04:05 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
High
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
3/25
06:00 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Neutral
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
2/26
12:50 pm
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
Low
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
2/15
07:47 am
rani
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week [Yahoo! Finance]
Medium
Report
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week [Yahoo! Finance]
2/7
08:28 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
2/5
04:50 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC [Yahoo! Finance]
High
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC [Yahoo! Finance]
2/5
04:05 pm
rani
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Neutral
Report
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC